UNLOCKING THE POWER OF PRECISION MEDICINE PERSONALIZED TREATMENTS FOR A HEALTHIER FUTURE

Main Article Content

Dr. Suresh Kanna Subramaniam
Dr. Umashankar. R.
Dr. Karthikeya. T. M.
Dr. Vinatha. M. C.

Keywords

healthcare, healthy, human, life, patients, precision medicine, testing

Abstract

The convergence of artificial intelligence (AI) and precision medicine represents a groundbreaking shift in healthcare. By harnessing the power of AI to analyze extensive patient data, including genomics, medical records, and clinical trial information, we can achieve more accurate diagnoses, tailor treatment plans to individual characteristics, and detect diseases earlier. This not only leads to improved patient outcomes but also accelerates drug discovery and reduces healthcare costs by optimizing treatment strategies. Nevertheless, this transformative potential comes with ethical and regulatory considerations, such as data privacy and algorithm fairness. Collaboration between healthcare professionals, data scientists, and geneticists is crucial for effective implementation, and ongoing research is essential to refine AI algorithms and ensure their seamless integration into clinical practice. As we continue to advance in this field, the convergence of AI and precision medicine holds promise for addressing complex healthcare challenges and providing personalized, effective care at scale.

Abstract 119 | pdf Downloads 21

References

1. Topol, E. J. High‐performance medicine: the convergence of human and artificial intelligence. Nat. Med. 25, 44–56 (2019).
2. Hashimoto, D.A. et al Artificial intelligence in surgery: promises and perils. Ann. Surg. 268, 70–76 (2018).
3. Mayo, R.C. & Leung, J. Artificial intelligence and deep learning ‐ radiology's next frontier? Clin. Imaging 49, 87–88 (2018).
4. Wang, F. & Preininger, A. AI in health: state of the art, challenges, and future directions. Yearb. Med. Inform. 28, 16–26 (2019).
5. McGinnis, J.M. et al The case for more active policy attention to health promotion. Health Aff. (Millwood) 21, 78–93 (2002).
6. Seidman EG, Furst DE. Pharmacogenetics for the individualization of treatment of rheumatic disorders using azathioprine. J Rheumatol. 2002; 29(12): 2484–2487.
7. Deverka PA, McLeod HL. Harnessing economic drivers for successful clinical implementation of pharmacogenetic testing. Clin Pharmacol Ther. 2008; 84(2): 191–193.
8. Manolopoulos VG. Pharmacogenomics and adverse drug reactions in diagnostic and clinical practice. Clin Chem Lab Med. 2007; 45(7): 801–814.
9. Bakker JA, Drent M, Bierau J. Relevance of pharmacogenetic aspects of mercaptopurine metabolism in the treatment of interstitial lung disease. Curr Opin Pulm Med. 2007; 13(5): 458–463.
10. Madadi P, Ross CJ, Hayden MR, et al. Pharmacogenetics of neonatal opioid toxicity following maternal use of codeine during breastfeeding: a case-control study. Clin Pharmacol Ther. 2009; 85(1): 31–35.
11. Goldman L, Goldman JS . Precision medicine for clinicians: the future begins now [Editorial]. Ann Intern Med. 2019;170:660-1. [PMID: 31035289] doi:10.7326/M19-1034
12. Teutsch SM, Bradley LA, Palomaki GE, et al; EGAPP Working Group. The Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Initiative: methods of the EGAPP working group. Genet Med. 2009;11:3-14. [PMID: 18813139] doi:10.1097/ GIM.0b013e 318184137c
13. Stoll K, Kubendran S, Cohen SA. The past, present and future of service delivery in genetic counseling: keeping up in the era of precision medicine. Am J Med Genet C Semin Med Genet. 2018; 178:24-37. doi:10.1002/ajmg.c.31602
14. Waseem N, Kircher S, Feliciano JL. Information blocking and oncology: implications of the 21st Century Cures Act and Open Notes. JAMA Oncol. 2021;7:1609-10. doi:10.1001/ jamaoncol.2021.3520
15. McGuire AL, Burke W. An unwelcome side effect of direct-toconsumer personal genome testing: raiding the medical commons. JAMA. 2008;300:2669-71. doi:10.1001/jama.2008.803
16. Artin MG, Stiles D, Kiryluk K, et al. Cases in precision medicine: when patients present with direct-to-consumer genetic test results. Ann Intern Med. 2019;170:643-50. doi:10.7326/ M18-2356
17. MedlinePlus. Genetic Testing: What Is Informed Consent? Accessed at https://medlineplus.gov/genetics/understanding/testing/ informedconsent on 4 January 2022.
18. Aspinall MG, Hamermesh RG. Realizing the promise of personalized medicine. Harv Bus Rev. 2007; 85(10): 108–17.
19. De Leon J. Pharmacogenomics the promise of personalized medicine for CNS disorders. Neuropsychopharmacology. 2009; 34(1): 159–172.
20. Ma N, Liao B, Zhang H, Wang L, Shan Y, Xue Y, et al. Transcription activator-like effector nuclease (TALEN)-mediated gene correction in integration-free b-thalassemia induced pluripotent stem cells. J Biol Chem. 2013;288(48): 34671–9, http://dx.doi.org/10.107 4/jbc.M113.496174.
21. Xie F, Ye L, Chang JC, Beyer AI, Wang J, Muench MO, et al. Seamless gene correction of b-thalassemia mutations in patient-specific iPSCs using CRISPR/Cas9 and piggyBac. Genome Res. 2014;24(9): 1526–33, http:// dx.doi.org/10.1101/gr.173427.114.